Table 4.
Patient characteristics for tet2-DMC–low and –high in the TCGA dataset*
| Characteristics | tet2-DMC–low | tet2-DMC–high | P |
|---|---|---|---|
| Total No. | 48 | 146 | |
| Age, mean (range), y | 49 (21–76) | 57 (18–88) | .0011 |
| Male sex, No. (%) | 25 (52) | 80 (55) | .87 |
| Bone marrow blasts at diagnosis, mean (range), % | 30 (0–94) | 39 (0–98) | .07 |
| WBC at diagnosis, mean (range), 103/uL | 29 (1–134) | 41 (1–298) | .16 |
| Cytogenetic risk group, No. (%) | <.0001 | ||
| Favorable | 31 (67) | 5 (3) | |
| Intermediate | 14 (30) | 99 (68) | |
| Poor | 1 (2) | 41 (28) | |
| Acute promyelocytic leukemia (M3), No. (%) | 18 (38) | 1 (1) | <.0001 |
| Overall survival, median (range), mo | 55 (0–85+) | 15 (0–95+) | .0003 |
| Mutations, No. (%) | |||
| ASXL1 | 0 (0) | 3 (6) | 1 |
| DNMT3A | 2 (12) | 17 (31) | .13 |
| FLT3-TKD | 17 (35) | 40 (29) | .47 |
| RAS | 2 (4) | 9 (6) | .73 |
| NPM | 8 (17) | 37 (26) | .24 |
| IDH1 | 1 (2) | 17 (12) | .08 |
| IDH2 | 0 (0) | 17 (12) | .008 |
| TET2 | 0 (0) | 8 (15) | .18 |
| TET2/IDH | 1 (2) | 41 (28) | <.0001 |
* The P values were computed from Fisher’s exact test for two-by-two contingency analyses, Mann-Whitney test to compare continuous variables (age, bone marrow blasts at diagnosis, and WBC at diagnosis), and the log-rank test for survival data. All P values were two-tailed, and the threshold of statistical significance was P < .05. TCGA = the Cancer Genome Atlas; tet2-DMCs = TET2-specific differentially methylated CpGs.